Evolving treatments for advanced gastric cancer: Appraisal of the survival trend

Michela Roberto, Adriana Romiti, Concetta Elisa Onesti, Angelo Zullo, Rosa Falcone, Paolo Marchetti

Research output: Contribution to journalReview articlepeer-review


ABSTRACT: Introduction and areas covered: We analysed the results of the main clinical studies looking at patients with advanced gastric or esophagogastric junction cancer, in order to differentiate between what is already clinical evidence and what is a promise for the cure of such patients. Thus, achievements from key studies, which had been purposely directed at chemotherapy, molecular target therapies and immunotherapy in both first and second-line setting were analysed. Metronomic chemotherapy, which consists of the administration of continuative low-dose anticancer drugs, was considered also. Expert commentary: It was found that patients included in experimental arms of randomized trials compared with controls have often benefited from a statistically significant extension of overall survival. However, further studies are awaited to bring new drugs into clinical practice and to validate candidate biomarkers predictive of response.

Original languageEnglish
Pages (from-to)717-729
Number of pages13
JournalExpert Review of Anticancer Therapy
Issue number7
Publication statusPublished - Jul 2 2016


  • Advanced gastric cancer
  • Chemotherapy
  • Immunotherapy
  • Metronomic chemotherapy
  • Target therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Evolving treatments for advanced gastric cancer: Appraisal of the survival trend'. Together they form a unique fingerprint.

Cite this